Bao, Y.; Zhang, Z.; He, X.; Cai, L.; Wang, X.; Li, X.
Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage. Curr. Oncol. 2022, 29, 6053-6067.
https://doi.org/10.3390/curroncol29090476
AMA Style
Bao Y, Zhang Z, He X, Cai L, Wang X, Li X.
Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage. Current Oncology. 2022; 29(9):6053-6067.
https://doi.org/10.3390/curroncol29090476
Chicago/Turabian Style
Bao, Yuwen, Zhuolin Zhang, Xuan He, Lele Cai, Xiao Wang, and Xin Li.
2022. "Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage" Current Oncology 29, no. 9: 6053-6067.
https://doi.org/10.3390/curroncol29090476
APA Style
Bao, Y., Zhang, Z., He, X., Cai, L., Wang, X., & Li, X.
(2022). Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage. Current Oncology, 29(9), 6053-6067.
https://doi.org/10.3390/curroncol29090476